Zalospirone in major depression: a placebo-controlled multicenter study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Serotonin (5-HT)1A receptor agonists, such as azapirones, have demonstrated potential antidepressant properties.
• Zalospirone is a novel cyclic imide compound investigated for its 5-HT1A partial agonist activity.

Purpose of the Study:

• To evaluate the efficacy and tolerability of zalospirone as a novel antidepressant treatment.
• To explore dose-response relationships for zalospirone in patients with unipolar major depression.

Main Methods:

• A 6-week, double-blind, randomized trial involving 287 outpatients with major depression (HAM-D score ≥ 20).
• Participants received placebo or fixed doses of zalospirone (6, 15, or 45 mg/day) administered thrice daily.
• Efficacy assessed using the Hamilton Rating Scale for Depression (HAM-D) and other outcome measures.

Main Results:

• The 45 mg/day dose of zalospirone significantly improved HAM-D scores compared to placebo from week 2 onwards (p < 0.05).
• Observed cases showed consistent clinical improvement with the high dose, but not in last-observation-carried-forward analyses.
• Lower doses (6 mg and 15 mg) showed trends towards improvement but were not statistically significant, suggesting a dose-response effect.
• The 45 mg dose was poorly tolerated, with dizziness and nausea reported in nearly half of patients and a 51% dropout rate by week 6.

Conclusions:

• Zalospirone at 45 mg/day demonstrated significant antidepressant efficacy in major depression, particularly in observed cases.
• Poor tolerability and high dropout rates at the effective dose limit its clinical utility.
• Further research is needed to determine if dose titration can improve tolerance to zalospirone.